This would enable direct testing of the translational potential of PTP1B inhibitors [20], which are in phase II clinical trials for diabetes treatment, and phase I clinical trials for breast cancer treatment (https://clinicaltrials.gov/ct2/show/NCT02524951), as treatments for atherosclerosis and reduction in CVD risk. Here, PTPN1 is linked to atherosclerosis.